表紙
市場調査レポート

ニードルフリー(無針)デバイス、技術および世界市場

Needle-Free Devices, Technologies and Global Markets

発行 BCC Research 商品コード 321389
出版日 ページ情報 英文 204 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
ニードルフリー(無針)デバイス、技術および世界市場 Needle-Free Devices, Technologies and Global Markets
出版日: 2015年01月01日 ページ情報: 英文 204 Pages
担当者のコメント
BCC Research社のレポートは、Reuter、Wall Street Journal、Fortuneなどで引用されることも多く、それぞれの業界の識者の意見として重きを置かれています。同社レポートを複数冊ご購入の場合年間パッケージのご契約がお得です。詳細は右の担当者のおすすめ商品よりご覧下さい。
概要

2013年における世界のニードルフリー(無針)技術市場は9億6,360万米ドルに達しました。同市場は2014年に11億米ドルへ拡大し、2014年から2019年の期間中は14.3%のCAGRで推移し、2019年に21億米ドルへ達すると予測されています。

当レポートでは、世界のニードルフリーデバイス市場について調査し、世界市場と関連技術の概要、市場動向の分析と予測、地域別の分析、市場影響因子および市場機会の分析、ニードルフリードラッグデリバリーデバイスの分析、市場戦略、競合情勢、規制構造および価格・医療費償還に関する議論、および主要企業のプロファイルなどをまとめています。

第1章 イントロダクション

第2章 サマリー

第3章 ドラッグデリバリーデバイス

  • ヒトの皮膚の構造
  • ドラッグデリバリーシステム・技術の概要
  • 技術によるドラッグデリバリーの分類
  • 投与経路によるドラッグデリバリーの分類
  • 注射または非経口ドラッグデリバリー
  • 経肺ドラッグデリバリー
  • 経鼻ドラッグデリバリー
  • 口腔粘膜ドラッグデリバリー
  • 直腸ドラッグデリバリー
  • 眼部ドラッグデリバリー
  • 経皮ドラッグデリバリー
  • ドラッグデリバリーのより良い手法の必要性
  • 継続中の研究分野

第4章 ニードルフリー(無針)技術およびドラッグデリバリーデバイス

  • ニードルフリードラッグデリバリーデバイス・タイプ
  • ニードルフリーデバイスの歴史
  • ニードルフリーデバイスの市場ニーズ
  • ニードルフリー技術のメリット

第5章 ニードルフリー(無針)デバイスのアプリケーション

  • ニードルフリーデバイスのアプリケーション
  • 疼痛管理
  • ワクチンデリバリー
  • インスリンデリバリー
  • 小児ドラッグデリバリー

第6章 無針注射器

  • イントロダクション
  • 無針注射器のタイプ
  • 無針注射器のコンポーネント
  • オペレーションのメカニズム
  • 原材料および主な無針注射器の設計
  • 無針注射器のアプリケーション
  • 無針注射器のメリット・デメリット
  • 臨床課題とアンメットニーズ
  • 将来の発展

第7章 吸入技術

  • 経肺ドラッグデリバリー
  • 吸入技術
  • 歴史的背景
  • 吸入技術の臨床的ニーズ
  • 吸入のタイプ
  • 将来の発展

第8章 経皮パッチ技術

  • 経皮ドラッグデリバリー
  • 経皮パッチ技術
  • 臨床的ニーズ
  • 歴史的背景
  • 経皮パッチのタイプ
  • 経皮パッチのコンポーネント
  • その他の投薬形態に勝る経皮パッチのメリット
  • 経皮パッチにおける新たな革新
  • 経皮パッチの限界
  • 経皮デリバリーの臨床上の課題
  • 将来の発展

第9章 その他の新しいニードル技術

  • マイクロニードル
  • ペン型ニードル

第10章 ニードルフリー(無針)デバイス市場評価

  • ドラッグデリバリーデバイス
  • 世界のニードルフリー技術市場
  • 世界市場:地域別
  • 世界市場:区分別
  • 世界市場:アプリケーション別
  • 市場成長の促進因子・阻害因子
  • 競合情勢

第11章 市場戦略

  • ニードルフリーデバイス市場戦略
  • 過去数年間の主要な戦略的イベント

第12章 上市・パイプライン製品

  • 主な上市製品
  • 経皮パッチ
  • その他の新しいニードル技術
  • 主なパイプライン製品
  • 定量吸入器(MDI)
  • 経皮パッチ
  • その他の新しい技術

第13章 規制構造

  • 地域的な規制構造
  • 米国
  • EU
  • 日本
  • その他のアジア
  • FDAの技術的問題点
  • FDAのリコール・安全警報
  • 労働衛生・安全法
  • 米国
  • EU

第14章 価格・医療費償還

  • 地域的な医療費償還構造
  • 医療装置の価格動向

第15章 ニードルフリー(無針)デバイスの結論・展望

  • 主な市場影響因子
  • 人口統計・経済動向
  • 変化する医療産業の構造
  • 将来の展望

第16章 付録A:略語

第17章 付録B:ベンダープロファイル

第18章 付録C:業界・専門組織

図表

目次
Product Code: HLC178A

REPORT HIGHLIGHTS

The global market for needle free technologies reached $963.6 million in 2013. This market is expected to grow to $1.1 billion in 2014 and $2.1 billion in 2019, with a compound annual growth rate (CAGR) of 14.3%.

This report provides:

  • An overview of the global market for stem cells and related technologies.
  • Analyses of global market trends, with data from 2013, estimates for 2014, and projections of compound annual growth rates (CAGRs) through 2019.
  • A regional breakdown of the market with emphasis on the U.S., Europe, and Japan
  • Qualitative and quantitative factors that are driving the global needle free devices market
  • Analysis of needle free drug delivery devices including jet injectors, inhalers, transdermal patch and other novel needle technologies
  • Discussion on market strategy, the competitive landscape, regulatory structure, and pricing and reimbursement for the industry
  • Comprehensive company profiles of major players in the field.

SCOPE OF THE REPORT

This report is an analytical business tool whose primary purpose is to describe the thorough evaluation of the global market for needle-free devices and technologies.

The format of the study is organized around the following topics:

  • Detailed study around key diseases such as asthma and diabetes.
  • Detailed study around key issues associated with traditional needle-based drug delivery devices and technologies, including needle phobia and needlestick injuries.
  • Incidence needlestick injuries and prevalence of chronic diseases such as asthma and diabetes.
  • Regulatory structure.
  • Market characterization, segmentation and unmet need.
  • Market size of needle-free devices and technologies, excluding the market for drug sales, combined with various needle-free devices such as needle-free injectors, transdermal patches, inhalers and other novel needle technologies.
  • Market drivers and restraints.
  • Detailed market projections through 2019.
  • Competition and market shares.
  • Pricing and reimbursement.
  • Marketed and pipeline (research and development) products along with description, regulatory status and clinical trials.
  • Market strategy along with key mergers, acquisitions, partnership agreements and other company developments.
  • Observations and conclusions regarding the future market of needle-free devices and technologies.

ANALYST'S CREDENTIALS

Dr. Ritu Thakur is the author of this report. She is an independent consultant based in New Delhi, India. She has prior work experience with a Japan-based core industry leader and a U.K.-based leading market and business research firm. In her previous assignments, she has written many reports on pharmaceutical, medical and biotechnology areas.

Table of Contents

CHAPTER 1 - INTRODUCTION

  • NEEDLE-FREE DEVICES
  • STUDY BACKGROUND
  • STUDY GOALS AND OBJECTIVES
  • INTENDED AUDIENCE
  • SCOPE OF THE REPORT
  • METHODOLOGY AND INFORMATION SOURCES
  • ANALYST'S CREDENTIALS
  • RELATED BCC RESEARCH REPORTS
  • BCC RESEARCH WEBSITE
  • DISCLAIMER

CHAPTER 2 - SUMMARY

  • EXECUTIVE SUMMARY
  • SUMMARY TABLE: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES, THROUGH 2019 ($ MILLIONS)
  • SUMMARY FIGURE: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES, 2013-2019 ($ MILLIONS)

CHAPTER 3 - DRUG DELIVERY DEVICES

  • STRUCTURE OF HUMAN SKIN
    • EPIDERMIS
    • DERMIS
    • HYPODERMIS
  • OVERVIEW OF DRUG DELIVERY SYSTEMS AND TECHNOLOGIES
  • CLASSIFICATION OF DRUG DELIVERY ACCORDING TO TECHNOLOGY
    • SUSTAINED RELEASE DRUG DELIVERY
    • PRODRUGS
    • IMPLANTS AND INTRAUTERINE DEVICES
    • TARGETED DRUG DELIVERY
    • POLYMERIC DRUG DELIVERY
  • CLASSIFICATION OF DRUG DELIVERY BY ROUTE OF ADMINISTRATION
    • ORAL DRUG DELIVERY
      • Proteins and Peptides
      • Enzyme Inhibitors
      • Mucoadhesives
      • Encapsulation Technologies
        • TABLE 1: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
  • INJECTABLE OR PARENTERAL DRUG DELIVERY
    • Needle/Syringe Injections
    • Safety Syringes/Needle-Free Injectors
      • TABLE 2: ADVANTAGES AND DISADVANTAGES OF INJECTABLE DRUG DELIVERY
  • PULMONARY DRUG DELIVERY
    • TABLE 3: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
  • NASAL DRUG DELIVERY
    • TABLE 4: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
  • ORAL MUCOSAL DRUG DELIVERY
    • TABLE 5: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DELIVERY
  • RECTAL DRUG DELIVERY
    • TABLE 6: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
  • OCULAR DRUG DELIVERY
    • TABLE 7: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
  • TRANSDERMAL DRUG DELIVERY
    • Passive Methods
    • Active Methods
    • Combined Technologies
      • TABLE 8: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY
  • NEED FOR BETTER METHODS OF DRUG DELIVERY
  • AREAS OF ONGOING RESEARCH

CHAPTER 4 - NEEDLE-FREE TECHNOLOGY AND DRUG DELIVERY DEVICES

  • NEEDLE-FREE DRUG DELIVERY DEVICES AND TYPES
  • HISTORY OF NEEDLE-FREE DEVICES
  • MARKET NEED FOR NEEDLE-FREE DEVICES
    • NEEDLE PHOBIA
      • Vasovagal
      • Associative
      • Resistive
      • Hyperalgesic
      • Vicarious
    • NEEDLESTICK INJURY
      • Overview of Needlestick Injury
      • Incidence of Needlestick Injuries
        • TABLE 9: INCIDENCE OF NEEDLESTICK INJURIES BY GEOGRAPHY, 2013 (NO.)
        • FIGURE 1: INCIDENCE OF NEEDLESTICK INJURIES BY GEOGRAPHY, 2013 (% OF TOTAL)
      • Causes of Sharps Injuries
      • Cost of Needlestick Injuries
      • Needlestick Injury Prevention
  • ADVANTAGES OF NEEDLE-FREE TECHNOLOGY

CHAPTER 5 - NEEDLE-FREE DEVICE APPLICATIONS

  • APPLICATION OF NEEDLE-FREE DEVICES
    • TABLE 10: GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
    • FIGURE 2 GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, 2013-2019 ($ MILLIONS)
  • PAIN MANAGEMENT
    • Latest Developments in Needle-Free Pain Management
  • VACCINE DELIVERY
    • Latest Developments in Needle-Free Vaccine Delivery
    • Future Developments in Needle-Free Vaccine Delivery
  • INSULIN DELIVERY
    • Diabetes Overview
      • FIGURE 3 DISTRIBUTION OF DIABETES TYPES GLOBALLY, 2013 (% OF TOTAL DIABETES)
    • Epidemiology and Economic Burden
      • TABLE 11: PREVALENCE OF DIABETES BY GEOGRAPHY, 2013 ($ MILLIONS)
      • FIGURE 4: PREVALENCE OF DIABETES BY GEOGRAPHY, 2013` (% OF TOTAL)
    • Traditional Insulin Delivery Systems
    • Needle-Free Insulin Delivery Systems
    • Insulin Jet Injectors
    • Inhalable Insulin Devices
    • Insulin Spray Systems
    • Insulin Micropump
    • Insulin Port
    • Transdermal Insulin Patches
    • Insulin Nanopump
      • TABLE 12: COMPARISON BETWEEN PAINFUL AND PAINLESS NEEDLE-FREE INSULIN DRUG DELIVERY SYSTEMS
    • Future Prospective for Needle-Free Insulin Delivery Systems
  • PEDIATRIC DRUG DELIVERY
    • Needle-Free Injectors
    • Low Workload Jet Injectors for Routine Immunizations
    • Multi-Channel Jet Injectors for Simultaneous Vaccine Delivery
    • Transdermal Methods and Microneedle Technologies for Various Drug Delivery Applications

CHAPTER 6 - NEEDLE-FREE INJECTORS

  • INTRODUCTION
    • HISTORICAL BACKGROUND OF NEEDLE-FREE INJECTOR
    • CLINICAL NEED FOR NEEDLE-FREE INJECTORS
  • NEEDLE-FREE INJECTOR TYPES
    • NEEDLE-FREE INJECTORS TYPES BY MEDICATION
      • Liquid-Based Needle-Free Injectors
      • Powder-Based Needle-Free Injectors
      • Depot or Projectile Needle-Free injectors
    • NEEDLE-FREE INJECTOR TYPES BY DRUG DELIVERY
      • Intramuscular Injections
      • Subcutaneous Injections
      • Intradermal Injections
    • NEEDLE-FREE INJECTOR TYPES BY SOURCE OF POWER
      • Spring Powered
      • Compressed Gas Powered
    • NEEDLE-FREE INJECTORS BY USAGE TYPE
      • Single-Use Injectors
      • Disposable Injectors
      • Reusable Injectors
  • COMPONENTS OF NEEDLE-FREE INJECTORS
    • INJECTOR DEVICE AND DRUG RESERVOIR
    • NOZZLE
    • PRESSURE SOURCE
  • MECHANISM OF OPERATION
  • RAW MATERIALS AND KEY NEEDLE-FREE INJECTOR DESIGNS
    • RAW MATERIALS
    • KEY NEEDLE-FREE INJECTOR DESIGNS
      • Jet Injectors
      • Jet Injector Gun
      • Hypodermal Jet Injectors without a Needle
      • Low Workload Jet Injector
      • Multi-Channel Jet Injector
      • Biojector
      • Microjets
      • Intraject Technology
      • Mini-Ject Technology
      • Needle-Free, Auto and Pen Injectors
      • MadaJet
      • INJEX Needle-Free Injectors for Infiltration Anesthesia
  • NEEDLE-FREE INJECTOR APPLICATIONS
  • ADVANTAGES AND DISADVANTAGES OF NEEDLE-FREE INJECTORS
    • EFFICIENT DRUG DISTRIBUTION AND IMPROVED EFFICACY
    • GREATER PATIENT ACCEPTANCE AND COMPLIANCE
      • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NEEDLE-FREE INJECTORS
    • SUPERIOR SAFETY
    • RELIABILITY AND REPEATABILITY
    • FASTER INJECTION TIME
    • ELIMINATES SHARPS WASTE
  • CLINICAL CHALLENGES AND UNMET NEEDS
  • FUTURE DEVELOPMENTS

CHAPTER 7 - INHALER TECHNOLOGIES

  • PULMONARY DRUG DELIVERY
    • TABLE 14: IDEAL CHARACTERISTICS OF THERAPEUTIC AEROSOLS
    • TABLE 15: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
  • INHALER TECHNOLOGY
    • TABLE 16: ADVANTAGES AND DISADVANTAGES OF INHALER TECHNOLOGIES
  • HISTORICAL BACKGROUND
  • CLINICAL NEED FOR INHALER TECHNOLOGY
    • Epidemiology of Asthma
      • TABLE 17: PREVALENCE OF ASTHMA BY GEOGRAPHY, 2013 (MILLIONS)
      • FIGURE 5: PREVALENCE OF ASTHMA BY GEOGRAPHY, 2013 (% OF TOTAL)
    • Economic Burden of Asthma
  • TYPES OF INHALERS
    • MDI
      • TABLE 18: ADVANTAGES AND DISADVANTAGES OF METERED DOSE INHALERS
      • New Developments in MDI Technology
      • Advanced MDI and Use Enantiomer Preparations of Inhaled Drugs
      • Generic MDIs
      • Improved Patient Inhalation Coordination with Advanced MDI
      • Flow Gate Valve Technology in Spacers
      • Adaptive Aerosol Delivery Technology
      • Autohaler (Modified Form of pMDI)
        • TABLE 19: ADVANTAGES AND DISADVANTAGES OF F STANDARD PRESS AND BREATHE METERED DOSE INHALERS
    • DPI
      • New Developments in DPI Technology
      • Air Classifier Technology in Devices
      • Multiple Air Classifier Technology
      • Spiros Inhaler Technology
        • TABLE 20: ADVANTAGES AND DISADVANTAGES OF DRY POWDER INHALERS
      • MDI. vs DPI (Uniformity vs. Diversity)
        • TABLE 21: COMPARISON OF INHALERS: MDI VS. DPI
    • ADVANCES IN PULMONARY DRUG DELIVERY
      • Particle Engineering
      • Agglomerated Vesicle Technology
  • FUTURE DEVELOPMENTS

CHAPTER 8 - TRANSDERMAL PATCH TECHNOLOGIES

  • TRANSDERMAL DRUG DELIVERY
    • TABLE 22: PARAMETERS AFFECTING SELECTION OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
  • TRANSDERMAL PATCH TECHNOLOGY
    • TABLE 23: IDEAL PROPERTIES OF TRANSDERMAL DRUG DELIVERY SYSTEMS
  • CLINICAL NEED
  • HISTORICAL BACKGROUND
  • TYPES OF TRANSDERMAL PATCHES
    • Single-Layer Drug-in-Adhesive
    • Multilayer Drug-in-Adhesive
    • Reservoir
    • Matrix
      • Drug-in-Adhesive System
      • Matrix Dispersion System
    • Micro Reservoir System
    • Vapor Patch
      • TABLE 24: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL PATCHES
  • COMPONENTS OF A TRANSDERMAL PATCH
    • Polymer Matrix
    • Drug
    • Permeation Enhancers
    • Adhesive
    • Backing Laminates
    • Release Liner
    • Other Excipients
  • BENEFITS OF TRANSDERMAL PATCHES OVER OTHER DOSAGE FORMS
  • NEW INNOVATIONS IN TRANSDERMAL PATCHES
    • Dispenser for Transdermal Patches
    • Magnetophoresis Combined with Chemical Enhancers
  • LIMITATIONS OF TRANSDERMAL PATCHES
  • CLINICAL ISSUES OF TRANSDERMAL DELIVERY
  • FUTURE DEVELOPMENTS

CHAPTER 9 - OTHER NOVEL NEEDLE TECHNOLOGIES

  • MICRONEEDLES
    • HISTORICAL BACKGROUND
    • TYPES OF MICRONEEDLES
      • Solid Microneedles
        • Fabrication of Solid Microneedles
          • Silicon Microneedles
          • Metal Microneedles
          • Polymer Microneedles
          • Ceramic Microneedles
          • Microneedle Rollers
      • Coated Microneedles
      • Dissolving Microneedles
      • Hollow Microneedles
    • APPLICATION OF MICRONEEDLES
      • Blood Glucose Measurements
      • Transdermal Drug Delivery
        • Immunobiologicals
        • Bioactive Macromolecules (Biopharmaceuticals)
        • Drug Delivery
        • Diagnosis
        • Cosmetic Products
    • ADVANTAGES AND DISADVANTAGES OF MICRONEEDLES
      • TABLE 25: ADVANTAGES AND DISADVANTAGES OF MICRONEEDLES
    • ADVANCES IN DRUG DELIVERY BY MICRONEEDLES
    • CURRENT AND FUTURE DEVELOPMENTS
  • PEN NEEDLES
    • CONSTRUCTION AND DESIGN OF PEN NEEDLES
      • TABLE 26: ADVANTAGES AND DISADVANTAGES OF MICRONEEDLES
    • CURRENT AND FUTURE DEVELOPMENTS

CHAPTER 10 - NEEDLE-FREE DEVICE MARKET ASSESSMENT

  • DRUG DELIVERY DEVICES
  • GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET
  • GLOBAL MARKET BY GEOGRAPHIC REGION
    • TABLE 27: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES BY REGION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 6: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES BY REGION, 2013-2019 ($ MILLIONS)
  • GLOBAL MARKET BY SEGMENT
    • TABLE 28: GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, 2013-2019 ($ MILLIONS)
    • FIGURE 8: NEEDLE-FREE DRUG DELIVERY TECHNOLOGY MARKET BY SEGMENT, 2013 (% OF TOTAL MARKET)
  • GLOBAL MARKET BY APPLICATION
    • TABLE 29: GLOBAL NEEDLE-FREE TECHNOLOGY MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • FIGURE 9: NEEDLE-FREE TECHNOLOGY MARKET BY APPLICATION, 2013 (% OF TOTAL MARKET)
  • MARKET GROWTH DRIVERS AND RESTRAINTS
    • Growth Drivers
      • Increase in Disease Population Worldwide.
      • Needle Phobia and Increasing Awareness about the Risk of Needlestick Injuries
      • Increasing Demand for Painless Drug Delivery Technologies
      • Growing Demand for Minimally Invasive Delivery Methods
      • Demand for More Sophisticated Delivery Systems for Effective Treatment
      • Growing Demand for Drug-Device Combinations
      • Limitations of Oral Drug Delivery
      • Limitations of Hypodermic Needles
      • Growing Demand for Needle-Free Technologies for Chronic Pain Management
      • Increasing Awareness about the Safety and Efficacy of Drug Delivery Technologies
      • Rising Prevalence of Diabetes
      • Increasing Awareness about Pediatric Vaccinations
      • Increasing Use of Needle-Free Injections in Anesthesia Delivery
      • Booming Global Vaccine Market
      • Mass Immunization Programs
      • Cost-Efficient Drug Delivery
      • Growth of Biologics and Entry of Biosimilars in Leading Pharmaceutical Markets
      • Development of Home-Care and Self-Medication Devices
      • Growing Market for Injectable Medications
      • Growing Market for Injectable HGH
    • Growth Restraints
      • High Cost of Needle-Free Technology
      • Increasing Regulatory Scrutiny and Inefficient Manufacturing Processes
      • Downward Pricing Pressure, Increasing Material Cost and Inefficient Manufacturing Processes
      • Increasing Competition and Decreasing Profit Margins
      • Increasing Research and Development Cost
      • Shorter Product Life Cycles
      • Risks and Complications
  • COMPETITIVE LANDSCAPE
    • TABLE 30: GLOBAL NEEDLE-FREE DEVICE MARKET REVENUE SHARES, 2013 ($ MILLIONS/%)
    • FIGURE 10: GLOBAL NEEDLE-FREE DEVICE MARKET LEADERS, 2013 (% OF TOTAL MARKET)

CHAPTER 11 - MARKET STRATEGY

  • NEEDLE-FREE DEVICES MARKET STRATEGY
  • KEY STRATEGIC EVENTS DURING THE LAST FEW YEARS
    • TABLE 31: NEEDLE-FREE DEVICE MARKET, KEY MERGERS/ACQUISITIONS
    • Key Mergers and Acquisitions
      • OPKO Health's Acquisition of Inspiro Medical
      • Endo International's Acquisition of Zogenix' DosePro Migraine Therapy Business
      • North Coast Medical's Acquisition of ActivaTek
      • Teva Pharmaceutical's Acquisition of NuPathe
      • Teva Pharmaceutical's Acquisition of MicroDose Therapeutx
      • Becton Dickinson's Acquisition of Safety Syringes
      • Medical Marketing Berlin/Paketeria AG's Acquisition of INJEX Pharma
    • Key Product and Technology Developments
      • NxStage Announces FDA Clearance of a Single Needle Technology
      • Vaxxas' Nanopatch Garners WHO Support for Polio Vaccine Delivery
      • FDA Approves Use of bioCSL's Afluria Influenza Vaccine with PharmaJet Needle-Free Injector
      • Bioject Inc. Expands its Global Distribution Network
      • Glide Pharma Completed the Successful Proof-of-Concept Study with Octreotide
      • Crossject Launched Bioequivalence Clinical Study with Zeneo (Methotrexate)
      • Bioject Enters Into Agreement with Fondaco
      • Antares Pharma's Otrexup Injection Approved by the FDA
      • Zogenix Received FDA Approval for 4 mg Sumavel DosePro (Sumatriptan Injection)
      • 3M Co. Licensed Fentanyl Transdermal Patch Technology to Stada Arzneimittel
      • Adamis Pharmaceuticals Acquired Dry Powder Inhaler Technology from 3M Co.
      • Bioject Medical Technologies Featured on Bloomberg International
      • PharmaJet's Stratis Needle-Free Injector Achieved WHO PQS Certification
      • Glide Pharma Completed Design Optimization Agreement with Nypro Healthcare
      • Antares Pharma Obtained U.S. Patent for Vibex Technology
      • Zogenix Signs Co-promotion Deal for Needle-Free Migraine Treatment
      • INJEX Pharma Received FDA Clearance for the INJEX 30
      • Medical International Technology Gains Chinese SFDA Certification for Med-Jet
      • Bioject Medical Technologies to Supply ID Pens
      • Zogenix and Durect Signed Development and License Agreement

CHAPTER 12 - MARKETED AND PIPELINE PRODUCTS

  • KEY MARKETED PRODUCTS
    • NEEDLE-FREE INJECTORS
      • Antares Pharma
        • Medi-Jector Vision Needle-Free Injector
        • Vibex Pressure Assisted Auto Injection System
        • Pen Injector
        • Otrexup
      • Bioject Medical Technologies
        • Biojector 2000 Needle-Free Injection System
        • Vitajet Insulin Delivery System
        • Cool.click Needle-Free Injection System
        • SeroJet Needle-Free Injection System
        • ZetaJet Auto-Disable Needle-Free Delivery System
      • Endo International
        • Sumavel DosePro Needle-Free Delivery System
      • Activa Brand Products Inc.
        • AdvantaJet
      • D'Antonio Consultants International
        • LectraJet Disposable Syringe Jet Injector System
      • National Medical Products
        • J-Tip Needle-Free System
      • Medical International Technologies
        • Med-Jet Needle-Free System
      • PenJet Corp.
        • PenJet Needle-Free System
      • PharmaJet
        • Stratis Needle-Free System
      • Valeritas
        • Mini-Ject Needle-Free System
        • h-Patch
        • Micro-Trans
      • Akra Dermojet
        • Dermojet HR
        • Dermojet Polymedical with Interchangeable Injection Tips
        • Automatic Dermojet
      • Felton International
        • HSI-500 Needle-Free Injector
      • INJEX Pharma
        • INJEX 30 Multiple Application Needle-Free Device
        • Jet Syringe/Rojex Disposable, Single-Use Devices
        • INJEX 50 Needle-Free Injection
      • Keystone Industries
        • Syrijet Mark II
      • Glide Pharma
        • Glide SDI Drug Delivery System
      • The Medical House PLC (Subsidiary of Consort Medical)
        • mhi-500 Novel Needle-free Insulin Delivery System
        • Spring-Powered SQ-PEN
        • Bespak Drug Delivery Solutions
      • Shreya Life Sciences
        • Recojet Needle-Free Insulin Delivery Device
      • Merck Serono
        • SeroJet
      • Pfizer
        • PowderMed
      • Key Device Approvals by the FDA
        • TABLE 32: NEEDLE-FREE INJECTORS: KEY DEVICE APPROVALS BY THE FDA, 2005-2014
    • INHALERS
      • Short-Acting Bronchodilators
      • Corticosteroids
      • Combination Drugs
      • Key Marketed MDI Devices
        • TABLE 33: KEY METERED DOSE INHALERS ON THE MARKET
  • TRANSDERMAL PATCH
    • TABLE 34: TRANSDERMAL PATCH: KEY MARKETED DEVICES
  • OTHER NOVEL NEEDLE TECHNOLOGIES
    • TABLE 35: "OTHER" NOVEL NEEDLE TECHNOLOGY-BASED DEVICES ON THE MARKET
  • KEY PIPELINE PRODUCTS
    • NEEDLE-FREE INJECTORS
      • Antares Pharma
        • Vibex MTX
        • Vibex QS (QuickShot)
      • Bioject Medical Technologies
        • ID Pen Injector
        • Iject Needle-Free Injection
        • Jupiter Jet
      • Zogenix
        • Relday
      • Pulse NeedleFree Systems
        • Needle-Free Systems
      • Echo Therapeutics
        • Prelude SkinPrep System
      • American Medical Systems
        • JetTouch Needle-Free Injection System
      • Crossject Medical Technology
        • Zeneo Disposable, Prefilled, Needle-Free, Automatic Injection System
          • TABLE 36: KEY NEEDLE-FREE DEVICES IN THE PIPELINE
  • METERED DOSE INHALERS
    • Teva Pharmaceutical
      • Albuterol HFA MDI
      • Beclomethasone Dipropionate MDI
    • Sunovion
      • Levalbuterol HFA MDI
    • Solvay Pharmaceuticals and Nektar Therapeutics
      • Dronabinol MDI
    • GlaxoSmithKline
      • FP/SLM HFA MDI 50/25 mcg
      • TABLE 37: KEY METERED DOSE INHALERS IN THE PIPELINE
  • TRANSDERMAL PATCHES
    • Amnio Technology
      • PalinGen (Amniotic Membrane Patch)
    • ICURE Pharmaceutical Inc.
      • Donepezil Patch
      • Formoterol Patch
      • Oxybutynin Patch
    • Merz Pharmaceuticals GmbH
      • Overnight Intensive Patch
    • Mundipharma Research Ltd.
      • Buprenorphine Patch (Extended Release)
    • Tyndall National Institute
      • ImmuPatch
        • TABLE 38: KEY TRANSDERMAL PATCHES IN THE PIPELINE
  • OTHER NOVEL TECHNOLOGIES
    • Seagull Technology
      • SonoEye

CHAPTER 13 - REGULATORY STRUCTURE

  • REGIONAL REGULATORY STRUCTURES
  • UNITED STATES
  • EUROPEAN UNION
    • TABLE 39: DIFFERENCES IN REGULATORY APPROVAL IN THE U.S. VS. EUROPE
  • JAPAN
  • OTHER ASIA
    • China
      • Hong Kong
    • Korea
    • Taiwan
    • India
  • FDA TECHNICAL CONSIDERATIONS
  • FDA RECALLS AND SAFETY ALERTS
  • OCCUPATIONAL HEALTH AND SAFETY LAWS
  • UNITED STATES
  • Needlestick Safety and Prevention Act/Blood-Borne Pathogens Standard
  • EUROPEAN UNION

CHAPTER 14 - PRICING AND REIMBURSEMENT

  • REGIONAL REIMBURSEMENT STRUCTURES
    • UNITED STATES
      • Healthcare Common Procedure Coding System Code
        • TABLE 40: HCPCS 2014 CODE A4210: NEEDLE-FREE INJECTION DEVICE, EACH
      • Insurance and Reimbursement
    • EUROPE
    • JAPAN
    • OTHER ASIA
  • MEDICAL DEVICE PRICING TRENDS

CHAPTER 15 - CONCLUSIONS AND OUTLOOK FOR NEEDLE-FREE DEVICES

  • MAJOR MARKET INFLUENCES
    • SOCIAL FACTORS
    • TECHNOLOGICAL DEVELOPMENTS
      • Breath-Actuated Metered-Dose Inhalers
      • Novel Formulation Approaches and Technologies for Transdermal Patches
      • Innovations to Create Autoinjector Syringes to Prevent Unnecessary Contamination
      • Laser-Powered Needle-Free Injections
      • Other Advanced Transdermal Drug Delivery Technologies
      • Next-Generation Needle-Free Drug Injector
      • Next-Generation Stamp-Sized Nanopatch
  • DEMOGRAPHIC AND ECONOMIC TRENDS
    • Increasing Aging Population
      • TABLE 41: ESTIMATED WORLD POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
      • FIGURE 11: ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 ($ MILLIONS)
      • TABLE 42: WORLD POPULATION BY SELECTED GEOGRAPHIC REGION, THROUGH 2030 (MILLIONS)
      • FIGURE 12: WORLD POPULATION BY SELECTED COUNTRy, 2000-2030 ($ MILLIONS)
    • U.S. Demographics
      • TABLE 43: U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, THROUGH 2030 (MILLIONS)
      • FIGURE 13: U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2030 (MILLIONS)
    • U.S. Gender, Age and Life Expectancy
      • TABLE 44: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
      • FIGURE 14: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
    • European Demographics
      • TABLE 45: EUROPEAN POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, THROUGH 2030 (MILLIONS)
      • FIGURE 15: EUROPEAN POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2030 (MILLIONS)
    • Japanese Demographics
      • TABLE 46: JAPANESE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, THROUGH 2030 (MILLIONS)
      • FIGURE 16: JAPANESE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2030 (MILLIONS)
    • Increasing Prevalence of Diabetes
      • TABLE 47: GLOBAL DIABETES PREVALENCE, 2013 AND 2030
    • Income Growth in Developing Markets
      • TABLE 48: PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2012-2015 (ANNUAL AVERAGE PERCENTAGE CHANGE)
  • CHANGING STRUCTURE OF THE HEALTHCARE INDUSTRY
    • Development of Home-Care and Self Medication Devices
    • Developments in Health Insurance and Reimbursement
  • FUTURE OUTLOOK

CHAPTER 16 - APPENDIX A: ABBREVIATION(S)

CHAPTER 17 - APPENDIX B: VENDOR PROFILES

  • ACTIVA BRAND PRODUCTS INC.
  • AKRA DERMOJET
  • ALKERMES PLC
  • ALZA CORP.
  • AMNIO TECHNOLOGY LLC.
  • ANTARES PHARMA INC.
  • ARADIGM CORP.
  • ASTELLAS PHARMA INC.
  • ASTRAZENECA PLC
  • BATTELLE
  • BESPAK EUROPE LTD.
  • BIOJECT MEDICAL TECHNOLOGIES
  • BRISTOL-MYERS SQUIBB
  • CAMBRIDGE CONSULTANTS LTD.
  • CLEARSIDE BIOMEDICAL INC.
  • CORIUM INTERNATIONAL INC.
  • COVIDIEN
  • CROSSJECT
  • CYDEX PHARMACEUTICALS INC.
  • D'ANTONIO CONSULTANTS INTERNATIONAL
  • DR. REDDY'S LABORATORIES LTD.
  • DUOJECT MEDICAL SYSTEMS INC.
  • DURECT CORP.
  • ECHO THERAPEUTICS
  • ELI LILLY & CO.
  • ENDO INTERNATIONAL
  • EUROJET MEDICAL INC.
  • FERNDALE PHARMA GROUP INC.
  • FERRING PHARMACEUTICALS INC.
  • GERRESHEIMER AG
  • GLAXOSMITHKLINE PLC
  • GLIDE PHARMACEUTICALS TECHNOLOGIES LTD.
  • HASELMEIER GMBH
  • INJEX PHARMA AG
  • INTERCELL AG
  • JCR PHARMACEUTICALS CO. LTD.
  • KEYSTONE INDUSTRIES
  • LINEAGE THERAPEUTICS INC.
  • LOHMANN THERAPIE-SYSTEME AG
  • MALLINCKRODT PLC
  • MEDICAL INTERNATIONAL TECHNOLOGIES
  • MEDI-PATCH CLINIC
  • MERCK SERONO S.A.
  • MINNESOTA RUBBER & PLASTICS
  • MPI RESEARCH
  • MYLAN INC.
  • NANOPASS TECHNOLOGIES LTD.
  • NATIONAL MEDICAL PRODUCTS INC.
  • NEKTAR THERAPEUTICS
  • NOVARTIS
  • NOVEN PHARMACEUTICALS
  • NOVO NORDISK A/S
  • NYPRO INC.
  • OWEN MUMFORD LTD.
  • PACIRA PHARMACEUTICALS INC.
  • PATHEON
  • PENJET CORP.
  • PFIZER INC.
  • PHARMAJET INC.
  • PSIVIDA CORP.
  • PULSE NEEDLE-FREE SYSTEMS INC.
  • QLT INC.
  • RETRACTABLE TECHNOLOGIES INC.
  • SANOFI-PASTEUR
  • SHL GROUP AB
  • TAKEDA
  • TAPEMARK
  • TEAM CONSULTING LTD.
  • TEVA PHARMACEUTICALS INDUSTRIES LTD.
  • THERAJECT INC.
  • TRANSPHARMA MEDICAL LTD.
  • VALERITAS INC.
  • VAXXAS PTY LTD.
  • YPSOMED HOLDING AG
  • ZOGENIX

CHAPTER 18 - APPENDIX C: INDUSTRY AND PROFESSIONAL ORGANIZATIONS

  • AMERICAN ASSOCIATION FOR RESPIRATORY CARE
  • ASSOCIATION OF NEEDLE-FREE INJECTION MANUFACTURERS
  • CENTER FOR DEVICES AND RADIOLOGICAL HEALTH
  • CENTERS FOR MEDICARE & MEDICAID SERVICES
  • DEPARTMENT OF HEALTH AND HUMAN SERVICES
  • EUDAMED
  • FOOD AND DRUG ADMINISTRATION
  • IFPMA
  • INTERNATIONAL DIABETES FEDERATION
  • INTERNATIONAL ASSOCIATION FOR THE STUDY OF OBESITY
  • ISIPS
  • NATIONAL CENTER FOR BIOTECHNOLOGY INFORMATION
  • NATIONAL INSTITUTE ON AGING
  • OECD
  • OPTICAL SOCIETY
  • PATH
  • PMDA
  • USAMRIID
  • WORLD HEALTH ORGANIZATION

LIST OF TABLES

  • SUMMARY TABLE: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES, THROUGH 2019 ($ MILLIONS)
    • TABLE 1: ADVANTAGES AND DISADVANTAGES OF ORAL DRUG DELIVERY
    • TABLE 2: ADVANTAGES AND DISADVANTAGES OF INJECTABLE DRUG DELIVERY
    • TABLE 3: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
    • TABLE 4: ADVANTAGES AND DISADVANTAGES OF NASAL DRUG DELIVERY
    • TABLE 5: ADVANTAGES AND DISADVANTAGES OF ORAL MUCOSAL DELIVERY
    • TABLE 6: ADVANTAGES AND DISADVANTAGES OF RECTAL DRUG DELIVERY
    • TABLE 7: ADVANTAGES AND DISADVANTAGES OF OCULAR DRUG DELIVERY
    • TABLE 8: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL DRUG DELIVERY
    • TABLE 9: INCIDENCE OF NEEDLESTICK INJURIES BY GEOGRAPHY, 2013 (NO.)
    • TABLE 10: GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
    • TABLE 11: PREVALENCE OF DIABETES BY GEOGRAPHY, 2013 ($ MILLIONS)
    • TABLE 12: COMPARISON BETWEEN PAINFUL AND PAINLESS NEEDLE-FREE INSULIN DRUG DELIVERY SYSTEMS
    • TABLE 13: ADVANTAGES AND DISADVANTAGES OF NEEDLE-FREE INJECTORS
    • TABLE 14: IDEAL CHARACTERISTICS OF THERAPEUTIC AEROSOLS
    • TABLE 15: ADVANTAGES AND DISADVANTAGES OF PULMONARY DRUG DELIVERY
    • TABLE 16: ADVANTAGES AND DISADVANTAGES OF INHALER TECHNOLOGIES
    • TABLE 17: PREVALENCE OF ASTHMA BY GEOGRAPHY, 2013 (MILLIONS)
    • TABLE 18: ADVANTAGES AND DISADVANTAGES OF METERED DOSE INHALERS
    • TABLE 19: ADVANTAGES AND DISADVANTAGES OF F STANDARD PRESS AND BREATHE METERED DOSE INHALERS
    • TABLE 20: ADVANTAGES AND DISADVANTAGES OF DRY POWDER INHALERS
    • TABLE 21: COMPARISON OF INHALERS: MDI VS. DPI
    • TABLE 22: PARAMETERS AFFECTING SELECTION OF DRUGS IN TRANSDERMAL DRUG DELIVERY SYSTEMS
    • TABLE 23: IDEAL PROPERTIES OF TRANSDERMAL DRUG DELIVERY SYSTEMS
    • TABLE 24: ADVANTAGES AND DISADVANTAGES OF TRANSDERMAL PATCHES
    • TABLE 25: ADVANTAGES AND DISADVANTAGES OF MICRONEEDLES
    • TABLE 26: ADVANTAGES AND DISADVANTAGES OF MICRONEEDLES
    • TABLE 27: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES BY REGION, THROUGH 2019 ($ MILLIONS)
    • TABLE 28: GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, THROUGH 2019 ($ MILLIONS)
    • TABLE 29: GLOBAL NEEDLE-FREE TECHNOLOGY MARKET BY APPLICATION, THROUGH 2019 ($ MILLIONS)
    • TABLE 30: GLOBAL NEEDLE-FREE DEVICE MARKET REVENUE SHARES, 2013 ($ MILLIONS/%)
    • TABLE 31: NEEDLE-FREE DEVICE MARKET, KEY MERGERS/ACQUISITIONS
    • TABLE 32: NEEDLE-FREE INJECTORS: KEY DEVICE APPROVALS BY THE FDA, 2005-2014
    • TABLE 33: KEY METERED DOSE INHALERS ON THE MARKET
    • TABLE 34: TRANSDERMAL PATCH: KEY MARKETED DEVICES
    • TABLE 35: "OTHER" NOVEL NEEDLE TECHNOLOGY-BASED DEVICES ON THE MARKET
    • TABLE 36: KEY NEEDLE-FREE DEVICES IN THE PIPELINE
    • TABLE 37: KEY METERED DOSE INHALERS IN THE PIPELINE
    • TABLE 38: KEY TRANSDERMAL PATCHES IN THE PIPELINE
    • TABLE 39: DIFFERENCES IN REGULATORY APPROVAL IN THE U.S. VS. EUROPE
    • TABLE 40: HCPCS 2014 CODE A4210: NEEDLE-FREE INJECTION DEVICE, EACH
    • TABLE 41: ESTIMATED WORLD POPULATION AND ANNUAL GROWTH BY SELECTED AGE GROUP AND SELECTED YEARS, THROUGH 2030 (MILLIONS)
    • TABLE 42: WORLD POPULATION BY SELECTED GEOGRAPHIC REGION, THROUGH 2030 (MILLIONS)
    • TABLE 43: U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, THROUGH 2030 (MILLIONS)
    • TABLE 44: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
    • TABLE 45: EUROPEAN POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, THROUGH 2030 (MILLIONS)
    • TABLE 46: JAPANESE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, THROUGH 2030 (MILLIONS)
    • TABLE 47: GLOBAL DIABETES PREVALENCE, 2013 AND 2030
    • TABLE 48: PROJECTED TRENDS IN PER CAPITA REAL GDP GROWTH BY REGION, 2012-2015 (ANNUAL AVERAGE PERCENTAGE CHANGE)

LIST OF FIGURES

  • SUMMARY FIGURE: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES, 2013-2019 ($ MILLIONS)
    • FIGURE 1: INCIDENCE OF NEEDLESTICK INJURIES BY GEOGRAPHY, 2013 `(% OF TOTAL)
    • FIGURE 2: GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, 2013-2019 ($ MILLIONS)
    • FIGURE 3: DISTRIBUTION OF DIABETES TYPES GLOBALLY, 2013 (% OF TOTAL DIABETES)
    • FIGURE 4: PREVALENCE OF DIABETES BY GEOGRAPHY, 2013` (% OF TOTAL)
    • FIGURE 5: PREVALENCE OF ASTHMA BY GEOGRAPHY, 2013 (% OF TOTAL)
    • FIGURE 6: GLOBAL MARKET FOR NEEDLE-FREE TECHNOLOGIES BY REGION, 2013-2019 ($ MILLIONS)
    • FIGURE 7: GLOBAL NEEDLE-FREE TECHNOLOGIES MARKET BY SEGMENT, 2013-2019 ($ MILLIONS)
    • FIGURE 8: NEEDLE-FREE DRUG DELIVERY TECHNOLOGY MARKET BY SEGMENT, 2013 (% OF TOTAL MARKET)
    • FIGURE 9: NEEDLE-FREE TECHNOLOGY MARKET BY APPLICATION, 2013 (% OF TOTAL MARKET)
    • FIGURE 10: GLOBAL NEEDLE-FREE DEVICE MARKET LEADERS, 2013 (% OF TOTAL MARKET)
    • FIGURE 11: ESTIMATED WORLD POPULATION BY SELECTED AGE GROUP AND SELECTED YEARS, 2000-2030 ($ MILLIONS)
    • FIGURE 12: WORLD POPULATION BY SELECTED COUNTRY, 2000-2030 ($ MILLIONS)
    • FIGURE 13: U.S. POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2030 (MILLIONS)
    • FIGURE 14: ESTIMATES OF ANTICIPATED U.S. LIFE EXPECTANCY AT BIRTH AND PROJECTIONS BY GENDER, 2005-2020 (YEARS)
    • FIGURE 15: EUROPEAN POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2030 (MILLIONS)
    • FIGURE 16: JAPANESE POPULATION ESTIMATES AND PROJECTIONS BY AGE GROUP, 2000-2030 (MILLIONS)
Back to Top